

Confidential Draft

For Immediate Release

For Further Information Contact:

Andrew Fisher at (301) 608-9292

Email: Afisher@unither.com

UNITED THERAPEUTICS AND NIH COOPERATE ON CLINICAL STUDY OF MULTI-GRAM ARGININE SUPPLEMENTATION FOR SICKLE CELL DISEASE

Silver Spring, MD, May 19, 2003—United Therapeutics Corporation (NASDAQ: UTHR) announced today that the National Institutes of Health (NIH) has agreed to use United Therapeutics' multi-gram drink-based formulation of arginine in a clinical study of sickle cell disease. A five-month study, *Evaluation of Potential Synergy of Combining Hydroxyurea with Nitric Oxide Donors on Fetal Hemoglobin Synthesis in Patients with Sickle Cell Anemia*, will be conducted by NIH with the multi-gram drink-based formulation of arginine provided by United Therapeutics.

"We are honored to assist NIH in developing innovative new therapies for this serious medical condition," said Martine Rothblatt, Ph.D., Chairman and CEO of United Therapeutics. "We are hopeful that one day the debilitating effects of sickle cell disease can be ameliorated with new medical treatments."

"The goal of this clinical study is to test whether increasing the body's nitric oxide level with arginine supplementation can increase fetal hemoglobin and prevent red blood cell sickling," said Mark T. Gladwin, M.D., Senior Principal Investigator, Critical Care Medicine Department, NIH Clinical Center; Laboratory of Chemical Biology, National Institute of Diabetes and Digestive and Kidney Diseases, NIH; Cardiovascular Branch, National Heart, Lung, and Blood Institute, NIH.

United Therapeutics is a biotechnology company focused on combating chronic and life-threatening cardiovascular, infectious and oncological diseases with unique therapeutic products.

DISCLAIMER: Conduct of this research study should not be viewed as an endorsement or implied endorsement by NIH, or its Institutes or Clinical Center, of United Therapeutics, its products and or services.

###